Founded in 2017 and headquartered in Waltham, Massachusetts, Alloy Therapeutics is a biotechnology ecosystem company dedicated to democratizing access to foundational drug discovery platforms and services. Its core mission is to make medicine more accessible by providing innovative and royalty-free platforms like Alloy-Gx, which features immunocompetent transgenic mice for superior in vivo human antibody discovery. Alloy Therapeutics focuses on enabling robust biologics discovery through a collaborative community of partners.

Notable figures associated with Alloy Therapeutics include its founder and key investors who support its mission of transforming drug discovery. The company has achieved significant milestones, such as developing industry-leading platforms that enhance the efficiency and effectiveness of antibody discovery. By fostering a community-driven approach, Alloy Therapeutics has made a substantial impact on the biotech industry, contributing to the acceleration of new therapeutic developments.